Company intelligence / Profile preview

VSA

Ownership: Private
Development stage: Other

Overview

VisionSys AI is an emerging technology company that recently pivoted from IT education to AI-powered healthcare and biotechnology. The company specializes in brain-machine interaction (BMI) and AI-driven clinical development solutions designed to transform the life sciences industry. In 2025, VisionSys AI announced a strategic acquisition of HopeAI, a firm whose proprietary platforms—PURE Evidence, SynthIPD, and CARA Design—optimize clinical trial design and accelerate drug development timelines. By integrating advanced AI algorithms with biomedical research, VisionSys AI aims to reduce the cost and duration of clinical trials for pharmaceutical and biotech partners.

Therapeutic areas: Other
Modalities: AI-powered clinical developmentBrain-machine interaction
Industry: Contract Research Organization

Partnerships

Mayo Clinic Platform_AccelerateMarinade Finance

Beyond the preview

Go deeper on VSA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VSA.